Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocular Therapeutix Inc OCUL

Healthcare
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular... see more

Recent & Breaking News (NDAQ:OCUL)

Ocular Therapeutix(TM) Provides Fourth Quarter and Year-End 2022 Results and Corporate Update

GlobeNewswire March 6, 2023

Ocular Therapeutix(TM) to Present at Cowen's 43rd Annual Healthcare Conference

GlobeNewswire February 28, 2023

Ocular Therapeutix(TM) To Report Fourth Quarter and Year-End 2022 Financial Results

GlobeNewswire February 21, 2023

Ocular Therapeutix(TM) Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

GlobeNewswire February 11, 2023

Ocular Therapeutix(TM) Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones

GlobeNewswire January 6, 2023

Ocular Therapeutix(TM) to Participate at Three Upcoming Investor Conferences

Business Wire November 8, 2022

Ocular Therapeutix(TM) Reports Third Quarter 2022 Financial Results and Business Update

Business Wire November 7, 2022

Ocular Therapeutix(TM) To Report Third Quarter 2022 Financial Results

Business Wire October 24, 2022

Ocular Therapeutix(TM) Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

Business Wire September 27, 2022

Ocular Therapeutix(TM) To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

Business Wire September 22, 2022

Ocular Therapeutix(TM) to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Business Wire September 7, 2022

Ocular Therapeutix(TM) to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Business Wire August 10, 2022

Ocular Therapeutix(TM) Reports Second Quarter 2022 Financial Results and Business Update

Business Wire August 8, 2022

Ocular Therapeutix(TM) To Report Second Quarter 2022 Financial Results

Business Wire July 25, 2022

Ocular Therapeutix(TM) Announces Organizational Changes to Support Development for Retinal Diseases

Business Wire June 8, 2022

Ocular Therapeutix(TM) to Present at the Jefferies Healthcare Conference

Business Wire June 1, 2022

Ocular Therapeutix(TM) Reports First Quarter 2022 Financial Results and Business Update

Business Wire May 9, 2022

Ocular Therapeutix(TM) To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

Business Wire May 3, 2022

Ocular Therapeutix(TM) to Report First Quarter 2022 Financial Results

Business Wire April 26, 2022

Ocular Therapeutix(TM) to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Business Wire April 25, 2022